Gut
Fragmented biomarker data, read weeks early.
Burak Multiomics
Burak Multiomics uses multi-omics velocity analysis to trace disease earlier and enable preventive interventions.
Three out of five people in the GCC are carrying a biological debt inside their bodies right now — and they don't know it.
Then, one day, someone in the prime of their life collapses, or doesn't wake up. We call it fate. It wasn't fate. It was debt — quietly compounding for years, invisible until the body could no longer carry it.
This is the gap our founder identified after 19 years working inside healthcare systems — across the NHS and Hamad Medical Corporation, Qatar. Not from the outside looking in, but from inside the system itself: real conversations with doctors, real pain points, watching the same silent pattern repeat across patients who looked perfectly fine right up until they weren't.
Burak Multiomics exists to make that debt visible before it calls itself in — turning fragmented health data into the kind of compounding intelligence that catches the pattern years before the crisis.
We're proud to be a QDB Accelerator Cohort 2026 Boot Camp winner, and part of the ongoing QDB Accelerator Program — backing that's helping us take this from a gap seen on the ground to something hospitals can pilot today.
BURAK uses straightforward, rules-based mathematics
The same kind of logic a senior clinician applies when reading a set of results: if this marker is at this level, it means this, and when you combine it with that marker, the picture tells you something specific.
We chose this approach because it is honest, traceable, and cost-effective at this stage — every score we produce can be explained in plain terms, with the exact numbers that drove it. We know that more advanced AI and machine learning models exist, and we intend to use them as we move into specific disease areas like diabetes, liver disease, and cancer screening.
But before we invest in that level of computational complexity, we wanted to first prove that the core idea works — that a well-designed, clinically grounded system can already give patients and doctors genuinely useful insight into what is happening inside the body. That is exactly what we are doing now
We connect what the gut is already saying, the story in the blood, and the signal of inflammation, so you see the full picture before it becomes a crisis.
Fragmented biomarker data, read weeks early.
Delayed disease detection treated as a risk multiplier.
High inflammatory amplifier with 3-of-5 signal confidence.
Disease develops gradually through measurable biological changes. The platform detects those signals early enough to change the decision.
Gut microbiome, blood biomarkers, and inflammatory markers are read as one picture.
Instead of isolated readings, Burak analyzes how quickly markers change over time.
Risk signals can surface weeks before symptoms, in time for clinical and lifestyle intervention.
Burak Multiomics is a data integration and analytics platform that unifies multi-omics datasets, including genomics, transcriptomics, proteomics, and metabolomics, into a single interpretable system.
Multi-omics data is often fragmented, hard to standardize, and difficult to interpret clinically. Burak integrates those layers so teams can move from isolated signals to a decision.
Clinical researchers, translational scientists, precision medicine teams, biotech and pharmaceutical organizations, and population health researchers.
A clinical layer connects molecular data to pathways and biomarkers. A population layer finds cohort trends and stratifies groups at scale.
Traditional tools often stay on a single omics layer or demand heavy technical effort to combine datasets. Burak is built as one platform for cross-layer exploration, from a single case to a large cohort.
Validate outcomes, integration fit, and reporting requirements before an annual license.